Scribe Raises $155.5 Million in IPO as CRISPR Cholesterol Drug Enters Human Trials

Lowering cholesterol is a field with multiple effective drugs, yet it remains constrained by the need for long-term medication and sustained treatment. Scribe Therapeutics is now entering the public market with an in vivo CRISPR therapy intended to provide effects lasting for years, once again subjecting the concept of expanding genetic medicine from rare diseases to common cardiovascular diseases to the dual tests of clinical development and the capital markets.

On July 27, Scribe completed its upsized initial public offering, issuing 9.867 million shares at $15 per share, including the underwriters’ full exercise of their option to purchase additional shares. The shares began trading on Nasdaq under the ticker “SCTX” on July 24. On the same day, existing partner Sanofi purchased 500,000 shares in a private placement at the same price, investing $7.5 million. Together, the two transactions generated approximately $155.5 million in gross proceeds, before deducting underwriting discounts, commissions, and other expenses.

The primary use of the funds is the candidate drug STX-1150. It uses an epigenetic silencing technology that Scribe calls ELXR to deliver active components into liver cells and suppress expression of the PCSK9 gene. With less PCSK9 protein, the liver’s ability to clear low-density lipoprotein cholesterol (LDL-C) from the blood is expected to improve. Unlike gene editing that cuts or rewrites DNA, this design does not alter the sequence of DNA letters, but whether it can deliver durability, precision, and acceptable safety in humans remains to be demonstrated clinically.

STX-1150 has entered a Phase 1 first-in-human trial in Australia, which is expected to enroll up to approximately 64 adults with elevated LDL-C and increased cardiovascular risk. The trial will begin with single ascending doses, followed by a dose-expansion stage. Its primary objective is to assess safety and tolerability, while changes in LDL-C and PCSK9, as well as pharmacokinetics, are secondary measures. The company expects to report preliminary data, including lipid-lowering activity, in the first half of 2027. Participants will be followed for one year after treatment, with longer-term follow-up also planned.

The most notable efficacy signal so far still comes from animals. In securities filings, Scribe said that in a small nonhuman primate study, a single injection of an STX-1150 prototype at 0.75 milligrams per kilogram reduced LDL-C by more than 50%, with the effect maintained for two years. However, that dose group included only four animals, while the control group included two, and the study was not designed with sufficient power to test statistical significance. The test article was also a prototype of the candidate drug, so the results cannot be used to directly infer efficacy or long-term safety in humans.

The filings show that the proceeds will be used to advance STX-1150, as well as the follow-on candidates STX-1200 and STX-1400, which target LPA and APOC3, and to support platform research and development and general operations. Sanofi’s concurrent investment extends the companies’ existing partnership, but the announcement did not disclose any new licensing programs or development commitments and should not be considered an endorsement of STX-1150’s clinical efficacy.

The IPO allows Scribe to cross a funding threshold, not a medical-evidence threshold. The company also warned in its filings that its existing funds, together with the net proceeds from the offering, will still be insufficient to carry any program all the way through regulatory approval. The next critical milestone will be the first human data: beyond how much LDL-C can be reduced, the more important questions concern liver responses, immune risks, unintended gene regulation, and how long the silencing effect can be maintained in humans.